Long-term exposure to trihalomethanes in drinking and swimming pool water increases the risk for CLLOctober 22, 2023B Cell Lymphoma
CAR T-cell therapy safe for older patients with relapsed or refractory DLBCLOctober 22, 2023B Cell Lymphoma
Acalabrutinib and zanubrutinib have similar efficacy in CLL, shows a matching-adjusted indirect comparisonOctober 22, 2023B Cell Lymphoma
Upfront ASCT overcomes the survival advantage provided by pre-transplant HDAC induction in MCLOctober 22, 2023B Cell Lymphoma
Ibrutinib and bortezomib combo durably effective in relapsed or refractory MCL with high-risk featuresOctober 22, 2023B Cell Lymphoma
Ibrutinib maintenance after frontline induction is effective in mantle cell lymphomaOctober 22, 2023B Cell Lymphoma
High-dose methotrexate does not reduce CNS progression risk in high-risk aggressive BCLOctober 22, 2023B Cell Lymphoma
Second-line vs later-line zanubrutinib improves survival in relapsed or refractory MCLOctober 22, 2023B Cell Lymphoma
Second-line axi-cel therapy yields high response rates in high-risk relapsed or refractory LBCLOctober 22, 2023B Cell Lymphoma
Commentary: Genetics, prognosis score, and PI3K in MCL, October 2023 September 29, 2023B Cell Lymphoma
Chemosensitivity helps predict survival outcomes after CAR T-cell therapy for DLBCLSeptember 22, 2023B Cell Lymphoma
Radiation therapy achieves effective palliation in MCL patients undergoing CAR T‐cell therapySeptember 22, 2023B Cell Lymphoma
Past or active HBV infection associated with an increased risk for DLBCLSeptember 22, 2023B Cell Lymphoma
